The Latest Breaking News from Hercules Capital

Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc.

Analysts have provided the following ratings for Hercules Capital (NYSE:HTGC) within the last quarter:

Akero Therapeutics Inc (NASDAQ:AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE:PFE) at $9.90 per share.  The company also announced a term loan facility providing Akero with access to up to $100 million from Hercules Capital Inc (NYSE:HTGC), of which $10 million will be drawn at transaction close.  Together with existing cash, proceeds will support…

Over the past 3 months, 4 analysts have published their opinion on Hercules Capital (NYSE:HTGC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.